Fig. 2From: Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockadeMaximum intensity projection images of two whole-body 18Â F-FDG PET/CT studies. Panel a shows the PETCT from 11/20/15, early in the course of immunotherapy. Panel b shows the PET/CT from 2/11/16, after completion of induction ipilimumab/nivolumab. Arrows indicate the increased metabolic glucose consumption in bilateral inguinal, iliac, axillary lymph nodes as well as the spleen, highly suggestive of immune activationBack to article page